T-CELL THERAPY EFFICACY
The advancement of immunotherapies, including CAR-T cell treatments, has driven a growing need for more predictive preclinical models and technologies capable of upscaling their tests in a miniaturized format. Addressing this, RoukenBio and ScreenIn3D have partnered to deliver next-generation 3D in vitro platforms that better replicate the tumour microenvironment.
Chimeric Antigen Receptor T-cell (CAR-T) therapies are approved for the treatment of several haematological malignancies. However, their clinical success against the majority of solid tumour types has been limited thus far. The need for physiologically relevant, more complex in vitro models of cancer is steadily increasing due to the emergence of immunotherapeutic approaches such as cell therapies but also drugs that actively target the immune system within the tumour microenvironment (TME). Furthermore, an increasing interest in precision treatment of cancer patients and the rise of combination of anti-cancer therapies has highlighted a gap for 3D tumour models in efficacy tests. Miniaturization facilitates increased data generation, especially when using
clinical samples.
To meet this growing demand, ScreenIn3D has formed a strategic partnership with RoukenBio, bringing together RoukenBio’s expertise in immunology and bespoke assay development with ScreenIn3D’s cutting-edge 3D miniaturized microfluidic technology. This collaboration enables us to deliver advanced, physiologically relevant assays that accelerate and de-risk your drug discovery
efforts.
